Glucagon-like Peptide-1 and Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Coronary Stenosis
NCT02602600 on ClinicalTrials.gov · last registry update 2018-07-11
A small phase 4 — 33 participants, against a typical 75. The sponsor logged completion for 18 April 2017. Primary outcome, as filed: Change from baseline in Coronary Flow Reserve.
- Status
- COMPLETED
- Phase
- P4
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- Eva Prescott
- Sponsor type
- Other
- Enrollment
- 33
- Started
- 2015-11-19
- Primary completion
- 2017-04-18 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change from baseline in Coronary Flow Reserve
Conditions studied
Microvascular Angina
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.